Planview Announces Strategic Acquisitions of Clarizen and Changepoint to Accelerate Strategy to Delivery for Enterprises
Planview, a global leader in Portfolio Management and Work Management, today announced the company has entered into definitive agreements to acquire Clarizen and Changepoint, leading enterprise Project Portfolio Management (PPM) providers.
Across industries, enterprises are transforming their businesses to be digital-first. This shift has only accelerated during the COVID-19 pandemic, and what’s emerged is a new and enduring way of working that’s flexible, highly distributed, and digital. As increasingly dispersed teams embrace new tools and processes to meet the evolving needs of their customers, visibility and connectivity across the enterprise have never been more critical. The market demands a comprehensive software platform that can connect strategy to delivery across siloed workstreams and disciplines – capabilities best provided through PPM and Agile.
The combination of Planview, Clarizen, and Changepoint creates a unique platform enabling organizations to better collaborate, deliver, and thrive in this new world of work. Backed by TPG Capital and TA Associates, the combination harnesses the capabilities of three leading providers to deliver customers an unmatched level of expertise, IP, and resources to ensure their most important outcomes are delivered with efficiency, urgency, and transparency.
“In today’s environment, enterprises are looking for partners with the vision, expertise, and scale to help them navigate and excel in our all-digital world,” said Greg Gilmore, CEO of Planview. “Planview, Clarizen, and Changepoint are all leaders, and together, our customers create an exceptional community of PMOs, PPM and Professional Services Automation (PSA) practitioners. Collectively, there is no better platform to drive innovation and fuel the transformation of strategy to delivery.”
Since inception, Planview has focused on partnering with enterprises to help them re-imagine the ways they plan and manage work. With Clarizen and Changepoint’s leadership and category expertise, Planview will provide customers of all sizes with a robust community and end-to-end offering that enables them to meet their unique business goals and drive better business outcomes. In addition to leading Enterprise Agile Planning and Kanban from Planview, Clarizen and Changepoint customers will benefit from the expanded resources that Planview delivers.
“We’re thrilled to be joining forces with two organizations that share our core belief of putting customers at the heart of everything we do,” said Matt Zilli, CEO of Clarizen. “By bringing together these companies, customers will have access to a portfolio of industry leading solutions from three world-class companies, as well as new innovation as we focus on providing even more value to our customers.”
“In order to achieve meaningful business outcomes, organizations need to be adaptable and nimble while ensuring alignment from strategic planning to delivery,” said Matt Scheuing, CEO of Changepoint. “We look forward to working with the Planview and Clarizen teams and believe the combination of exceptional Portfolio and Work Management solutions, practitioners and experts will enable our customers to continue to succeed in an ever-changing business environment.”
Upon completion of the transactions, the Clarizen and Changepoint teams will join Planview as distinct business units, led by Matt Zilli and Matt Scheuing. Zilli and Scheuing will report into Planview CEO, Greg Gilmore. The transaction is expected to close in the first quarter of 2021. Terms of the transaction were not disclosed. To learn more, visit Planview.com.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: www.planview.com.
About Clarizen
Clarizen connects work across the enterprise, turning ideas into strategies, plans, and action. With Clarizen, organizations can work the way they want to work and have real time visibility into all their workstreams. This keeps teams focused on the things that matter, delivers results faster, and helps them exceed their company goals and customers’ expectations. Thousands of global customers, such as Jones Lang LaSalle (JLL), Siemens, De Beers, Ricoh, Box and Shaw Industries, across a wide variety of industries in 124 countries rely on Clarizen to help them achieve their business goals. To learn more, visit www.clarizen.com.
About Changepoint
Changepoint transforms project, engagement and application portfolios with an adaptable, intuitive and intelligent platform that is configurable for an agile business. Changepoint’s built-for-purpose portfolio management solutions are designed for strategic transformation leaders, project management offices, services organizations, and IT leaders. Hundreds of global customers partner with us to make informed and innovative business decisions, enable transformation, maximize profit, drive visibility, and align outcomes to strategy. Achieve better business outcomes at www.changepoint.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005685/en/
Contact information
Planview
Leslie Marcotte
719-439-4921
lmarcotte@planview.com
Clarizen
Andrew Ryan, Actual Agency
954-495-6786
andrew.ryan@actual.agency
Changepoint
Andy Tolton
425-681-2770
andy.tolton@changepoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom